Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

Abstract Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virologic failure risks in real-world settings. Methods T...

Full description

Bibliographic Details
Main Authors: Anthony M. Mills, Laurence Brunet, Jennifer S. Fusco, Michael B. Wohlfeiler, Cindy P. Garris, Alan K. Oglesby, Joseph M. Mrus, Philip C. Lackey, Gregory P. Fusco
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-11-01
Series:Infectious Diseases and Therapy
Subjects:
Antiretroviral therapy
ART-naïve
Cohort
Core agents
Observational
Virologic failure
Online Access:http://link.springer.com/article/10.1007/s40121-019-00274-5

Internet

http://link.springer.com/article/10.1007/s40121-019-00274-5

Similar Items